DE60333460D1 - Methoden und zusammensetzungen zur beeinflussung d - Google Patents

Methoden und zusammensetzungen zur beeinflussung d

Info

Publication number
DE60333460D1
DE60333460D1 DE60333460T DE60333460T DE60333460D1 DE 60333460 D1 DE60333460 D1 DE 60333460D1 DE 60333460 T DE60333460 T DE 60333460T DE 60333460 T DE60333460 T DE 60333460T DE 60333460 D1 DE60333460 D1 DE 60333460D1
Authority
DE
Germany
Prior art keywords
catenin
beta
modulators
present
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333460T
Other languages
English (en)
Inventor
Yinon Ben-Neriah
Irit Alkalay
Sharon Amit
Yaara Birman
Ada Hatzubai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE60333460D1 publication Critical patent/DE60333460D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60333460T 2002-04-29 2003-04-28 Methoden und zusammensetzungen zur beeinflussung d Expired - Lifetime DE60333460D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14940402A IL149404A0 (en) 2002-04-29 2002-04-29 METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
PCT/IL2003/000340 WO2003092719A2 (en) 2002-04-29 2003-04-28 Methods and compositions for modulating beta-catenin phosphorylation

Publications (1)

Publication Number Publication Date
DE60333460D1 true DE60333460D1 (de) 2010-09-02

Family

ID=28460385

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333460T Expired - Lifetime DE60333460D1 (de) 2002-04-29 2003-04-28 Methoden und zusammensetzungen zur beeinflussung d

Country Status (8)

Country Link
EP (1) EP1528928B1 (de)
AT (1) ATE474588T1 (de)
AU (1) AU2003222426A1 (de)
DE (1) DE60333460D1 (de)
ES (1) ES2349498T3 (de)
IL (1) IL149404A0 (de)
PT (1) PT1528928E (de)
WO (1) WO2003092719A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986619A4 (de) * 2006-02-06 2010-04-28 Lixte Biotechnology Inc Verwendung von phosphatasen zur behandlung von tumoren durch n-cor-überexpression
EP2983661B1 (de) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulierungen von oxabicycloheptanen und oxabicycloheptenen
CA2981844A1 (en) * 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
KR102264305B1 (ko) * 2019-07-23 2021-06-14 한국생명공학연구원 인산화된 베타-카테닌에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551200A1 (de) * 1992-01-07 1993-07-14 National University Of Singapore Protein-Phosphatase-Inhibitoren zur Verwendung in der Therapie
JPH08500112A (ja) * 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
EP0988317B1 (de) * 1997-06-17 2008-04-23 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aib1, ein steroidrezeptor co-aktivator
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2001032708A1 (en) * 1999-11-05 2001-05-10 Forskarpatent I Syd Ab Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
EP1170008A1 (de) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
WO2002024941A2 (en) * 2000-09-22 2002-03-28 University Of Dundee Protein kinase regulation

Also Published As

Publication number Publication date
WO2003092719A3 (en) 2004-03-18
ES2349498T3 (es) 2011-01-04
IL149404A0 (en) 2002-11-10
PT1528928E (pt) 2010-10-26
ATE474588T1 (de) 2010-08-15
EP1528928A2 (de) 2005-05-11
EP1528928B1 (de) 2010-07-21
WO2003092719A2 (en) 2003-11-13
AU2003222426A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
DE602006021223D1 (de) Verfahren zur identifizierung von trpv2-modulatoren
EA200700255A1 (ru) Новый карбамилированный еро и способ его получения
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
ATE433447T1 (de) Pyrimiidinverbindungen
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
BRPI0606118A2 (pt) uma sìntese assimétrica de (s) - (+) -3- (aminometil) -5- ácido metilhexanóico
ES2162277T3 (es) Sustratos e inhibidores de enzimas proteoliticos.
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
DE602004029549D1 (de) Vorrichtung für vorhersage von muskel/skelett-erkrankungen
ATE311388T1 (de) Pyrimidotriazine als phosphataseinhibitoren
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE60320784D1 (de) Stände zur modulierung des knochenwachstums
ATE507209T1 (de) Referenzstandard zur charakterisierung von rosuvastatin
DE60333460D1 (de) Methoden und zusammensetzungen zur beeinflussung d
DE602006013688D1 (de) Neues verfahren zur herstellung von thoc
NO20033921L (no) Inhibitor av monoaminopptak
DE60215395D1 (de) Emulgierende formulierung auf backfettbasis für die zubereitung von kuchen und verfahren
ATE394480T1 (de) Kristallstruktur der glutamatracemase (muri)
ATE440848T1 (de) Synthese von proteaseinhibitorvorstufen
DE50203388D1 (de) Verbessertes verfahren zur herstellung von bisphosphiten
ATE516802T1 (de) Verfahren zur modulierung der phototoxizität